Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant

NCT05457959 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Never opened

Conditions

Diffuse Hemispheric Glioma, H3 G34-Mutant

Interventions

BIOLOGICAL: Dendritic Cell Tumor Peptide Vaccine
BIOLOGICAL: Ipilimumab
PROCEDURE: Leukapheresis
BIOLOGICAL: Nivolumab
DRUG: Placebo Administration
DRUG: Placebo Administration
DRUG: Poly ICLC
PROCEDURE: Resection

Sponsor

Jonsson Comprehensive Cancer Center